Author

J. M. Enserink

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:deconvolution· 1 Organism:Drosophila· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

D. S. Tadele· 2 shared A. Al Outa· 1 shared A. Frigessi· 1 shared A. Köhn-Luque· 1 shared B.-T. Gjertsen· 1 shared E. Harivel· 1 shared E. M. Myklebust· 1 shared F. Schjesvold· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. S. Tadele

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The human leukemic oncogene MLL-AF4 promotes hyperplastic growth of hematopoietic tissues in Drosophila larvae

J. A. Johannessen, M. Formica, N. R. Brathen, A. Al Outa, M. Aarsund, M. Therrien, J. M. Enserink, H. Knaevelsrud

This study uses a Drosophila model to show that MLL-AF4 promotes hematopoietic hyperplasia and that DOT1L inhibition can reverse the leukemia-like phenotype.

bioRxiv · Nov 8, 2022 · PreprintCancer Biology

Phenotypic deconvolution in heterogeneous cancer cell populations using drug screening data

A. Köhn-Luque, E. M. Myklebust, D. S. Tadele, M. Giliberto, L. Schmiester, J. Noory, E. Harivel, P. Arsenteva, S. M. Mumenthaler, F. Schjesvold, K. Tasken, J. M. Enserink, K. Leder, A. Frigessi, J. Foo

This paper introduces PhenoPop, a method to deconvolve tumor heterogeneity using drug screening data, identifying subpopulations with differential drug responses and their frequencies.

bioRxiv · Jan 17, 2022Cancer Biology

A cell competition-based drug screen identifies a novel compound that induces dual c-Myc depletion and p53 activation

D. S. Tadele, J. M. Robertson, R. Crispin, M. C. Herrera, M. Chlubnova, L. I. Piechaczyk, P. Ayuda-Duran, S. K. Singh, T. Gedde-Dahl, Y. Floisand, J. Skavland, J. Wesche, B.-T. Gjertsen, J. M. Enserink

This study identifies a novel compound, DJ34, that depletes c-Myc and activates p53, showing strong activity against leukemic stem cells across multiple cancer types.

bioRxiv · May 16, 2020 · PreprintCancer Biology